Our findings highlight the utility of G9A inhibition in addressing the growth of cancer cells and have exciting implications on the use of BIX-01294 and other epigenetic inhibitors in cancer therapy, especially in the context of solid tumors which are highly heterogeneous and frequently hypoxic. This evidence concerns the gene EHMT2 and cancer.